Aptose Enters Into Exclusive Worldwide License Agreement With Hanmi Pharmaceutical For Clinical-Stage Myeloid Kinome Inhibitor HM43239; Hanmi Will Receive An Upfront Payment Of $12.5M, Including $5M In Cash And $7.5M In Aptose Shares